Denise D Correa1, Jaya Satagopan2, Raymond E Baser2, Kenneth Cheung2, Elizabeth Richards2, Michael Lin2, Sasan Karimi2, John Lyo2, Lisa M DeAngelis2, Irene Orlow2. 1. From the Departments of Neurology (D.D.C., E.R., L.M.D.), Epidemiology and Biostatistics (J.S., R.E.B., K.C., I.O.), and Radiology (S.K., J.L.), Memorial Sloan-Kettering Cancer Center, New York; and Department of Neurology (D.D.C., M.L., L.M.D.), Weill Cornell Medical College, New York, NY. corread@mskcc.org. 2. From the Departments of Neurology (D.D.C., E.R., L.M.D.), Epidemiology and Biostatistics (J.S., R.E.B., K.C., I.O.), and Radiology (S.K., J.L.), Memorial Sloan-Kettering Cancer Center, New York; and Department of Neurology (D.D.C., M.L., L.M.D.), Weill Cornell Medical College, New York, NY.
Abstract
OBJECTIVE: The goal of this study was to assess whether the APOE ε4 allele and other APOE single nucleotide polymorphisms (SNPs) influence neuropsychological and neuroimaging outcomes in patients with brain tumors. METHODS: Two hundred eleven patients with brain tumors participated in the study. All patients completed standardized neuropsychological tests and provided a blood sample for APOE genotyping. Ratings of white matter abnormalities were performed on MRI scans. Patients were classified into 2 groups based on the presence (n = 50) or absence (n = 161) of at least one APOE ε4 allele. Additional APOE SNPs were genotyped in a subset of 150 patients. RESULTS: Patients with at least one APOE ε4 allele had significantly lower scores in verbal learning and delayed recall, and marginally significant lower scores in executive function, in comparison to noncarriers of an ε4 allele. Patients with at least one ε4 allele and history of cigarette smoking had significantly higher scores in working memory and verbal learning than ε4 carriers who never smoked. Nine additional APOE SNPs were significantly associated with attention and executive and memory abilities. There were no significant differences between ε4 carriers and noncarriers on the extent of white matter abnormalities on MRI. CONCLUSIONS: The findings suggest that patients with brain tumors who are carriers of the APOE ε4 allele may have increased vulnerability to developing memory and executive dysfunction, and that additional SNPs in the APOE gene may be associated with cognitive outcome.
OBJECTIVE: The goal of this study was to assess whether the APOE ε4 allele and other APOE single nucleotide polymorphisms (SNPs) influence neuropsychological and neuroimaging outcomes in patients with brain tumors. METHODS: Two hundred eleven patients with brain tumors participated in the study. All patients completed standardized neuropsychological tests and provided a blood sample for APOE genotyping. Ratings of white matter abnormalities were performed on MRI scans. Patients were classified into 2 groups based on the presence (n = 50) or absence (n = 161) of at least one APOE ε4 allele. Additional APOE SNPs were genotyped in a subset of 150 patients. RESULTS:Patients with at least one APOE ε4 allele had significantly lower scores in verbal learning and delayed recall, and marginally significant lower scores in executive function, in comparison to noncarriers of an ε4 allele. Patients with at least one ε4 allele and history of cigarette smoking had significantly higher scores in working memory and verbal learning than ε4 carriers who never smoked. Nine additional APOE SNPs were significantly associated with attention and executive and memory abilities. There were no significant differences between ε4 carriers and noncarriers on the extent of white matter abnormalities on MRI. CONCLUSIONS: The findings suggest that patients with brain tumors who are carriers of the APOE ε4 allele may have increased vulnerability to developing memory and executive dysfunction, and that additional SNPs in the APOE gene may be associated with cognitive outcome.
Authors: Tim A Ahles; Andrew J Saykin; Walter W Noll; Charlotte T Furstenberg; Stephen Guerin; Bernard Cole; Leila A Mott Journal: Psychooncology Date: 2003-09 Impact factor: 3.894
Authors: Katie M O'Brien; Irene Orlow; Cristina R Antonescu; Karla Ballman; Linda McCall; Ronald DeMatteo; Lawrence S Engel Journal: PLoS One Date: 2013-04-18 Impact factor: 3.240
Authors: Yanhong Liu; Renke Zhou; Erik P Sulman; Michael E Scheurer; Nicholas Boehling; Georgina N Armstrong; Spiridon Tsavachidis; Fu-Wen Liang; Carol J Etzel; Charles A Conrad; Mark R Gilbert; Terri S Armstrong; Melissa L Bondy; Jeffrey S Wefel Journal: Clin Cancer Res Date: 2015-04-22 Impact factor: 12.531
Authors: Brian D Gonzalez; Heather S L Jim; Margaret Booth-Jones; Brent J Small; Steven K Sutton; Hui-Yi Lin; Jong Y Park; Philippe E Spiess; Mayer N Fishman; Paul B Jacobsen Journal: J Clin Oncol Date: 2015-05-11 Impact factor: 44.544
Authors: D D Correa; J C Root; M Kryza-Lacombe; M Mehta; S Karimi; M L Hensley; N Relkin Journal: Brain Imaging Behav Date: 2017-12 Impact factor: 3.978
Authors: Denise D Correa; Maria Kryza-Lacombe; Raymond E Baser; Kathryn Beal; Lisa M DeAngelis Journal: J Neurooncol Date: 2016-01-06 Impact factor: 4.130
Authors: D D Correa; M Kryza-Lacombe; X Zhou; R E Baser; B J Beattie; Z Beiene; J Humm; L M DeAngelis; I Orlow; W Weber; J Osborne Journal: J Neurooncol Date: 2017-11-22 Impact factor: 4.130